The history of the erectile dysfunction drug presents a complex picture for investors. While the initial release generated substantial profits, the lapse of its exclusive rights opened the floodgates to off-brand alternatives, dramatically eroding market share. This presents a specific risk for firms banking on similar blockbuster products, suggest

The story of Viagra, and its parent company copyright, presents a intriguing case study for investors. At first a blockbuster drug, generating billions in income, its patent expiration created a deluge of generic competition , significantly impacting its market share . While specific firms may try to capitalize on male sexual dysfunction, the exist